|
|
||||||||
Clinical Chemistry, Vol 32, 5-12, Copyright © 1986 by American Association for Clinical Chemistry
SJ Soldin
This review deals briefly with the clinical pharmacology of digoxin and reviews in some depth the problems inherent in methods of digoxin measurement. Digoxin-like factors (materials that cross react in digoxin immunoassays) are discussed, and some current evidence suggesting the existence of a new hormone, endoxin (endogenous digoxin), is summarized.
The following articles in journals at HighWire Press have cited this article:
![]() |
C. Woodland, G. Koren, and S. Ito From Bench to Bedside: Utilization of an In Vitro Model to Predict Potential Drug-Drug Interactions in the Kidney: The Digoxin-Mifepristone Example J. Clin. Pharmacol., July 1, 2003; 43(7): 743 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. E. Azzazy, S.-H. Duh, A. Maturen, E. Schaller, L. Shaw, R. Grimaldi, G. Shock, and R. H. Christenson Multicenter study of Abbott AxSYM(R) Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors Clin. Chem., September 1, 1997; 43(9): 1635 - 1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. A. M. Qazzaz, S. L. Goudy, and R. Valdes Jr. Deglycosylated Products of Endogenous Digoxin-like Immunoreactive Factor in Mammalian Tissue J. Biol. Chem., April 12, 1996; 271(15): 8731 - 8737. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Lai, R. Swaminathan, C. O. Pun, and J. Vallance-Owen Limitations of Hemofiltration in Digoxin Overdose-Reply Arch Intern Med, November 1, 1986; 146(11): 2287 - 2288. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |